ProCE Banner Activity

iNNOVATE (PCYC-1127): Phase III Study of Ibrutinib/Rituximab in Waldenström Macroglobulinemia

Slideset Download
Conference Coverage
Planned interim analysis of phase III iNNOVATE study shows significant improvements in PFS with ibrutinib plus rituximab vs rituximab alone in patients with Waldenström macroglobulinemia.

Released: June 04, 2018

Expiration: June 03, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen